Rising Cancer Prevalence And Other Diseases Driving Demand For Epigenetics Market: A Key Factor Shaping the Future of the Epigenetics Market in 2025

What combination of drivers is leading to accelerated growth in the epigenetics market?
The escalating occurrence of cancer and other illnesses is profoundly impacting the expansion of the epigenetics market. As disease prevalence increases, so does the need for epigenetics. For example, in May 2024, the National Cancer Institute (NCI), a US government agency, reported nearly 20 million new cancer cases in 2022, leading to roughly 9.7 million deaths linked to the disease. Forecasts suggest that by 2040, the annual number of new cancer cases will rise to 29.9 million, while deaths associated with cancer will reach 15.3 million. Moreover, the Centers for Disease Control and Prevention (CDC) state that approximately 659,000 individuals in the United States succumb to heart disease annually. The rising occurrence of cancer and other illnesses necessitates testing and understanding the changes that occur in genes, inevitably boosting the usage and demand for epigenetics. Therefore, the increasing occurrence of cancer and other diseases propels the growth of the epigenetics market in forthcoming years.

Get Your Epigenetics Market Report Here:
https://www.thebusinessresearchcompany.com/report/epigenetics-global-market-report

What is the projected compound annual growth rate (CAGR) of the epigenetics market from 2025 to 2034, and what factors influence it?
Recent years have seen an explosive growth in the size of the epigenetics market. It is projected to expand from $10.65 billion in 2024 to $12.83 billion in 2025, with a compound annual growth rate (CAGR) of 20.4%. Several factors have led to this growth during the historic period, including increased funding for research, a rise in the incidence of chronic diseases, advances in personalized medicine and cancer research, as well as an aging population.

In the forthcoming years, the size of the epigenetics market is projected to experience a surge. It is predicted to increase to a value of $29.08 billion in 2029, marking a compound annual growth rate (CAGR) of 22.7%. Factors contributing to this projected growth during the forecast period include the development of epigenetic drugs, the application of epigenetics in environmental health and precision agriculture, support from regulatory bodies, and increasing patient awareness and advocacy. Key trends anticipated during this period encompass epitranscriptomics, single-cell epigenomics, epigenetic editing, epigenetic biomarkers, research into ageing and longevity, along with microbiome-epigenome interactions.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7070&type=smp

How are the latest trends influencing the growth of the epigenetics market?
Leading firms in the epigenetics market are concentrating their efforts on generating state-of-the-art solutions like DNA sequencing techniques to boost precision medicine and enhance the comprehension and outcomes of disease treatment. DNA sequencing methods, which establish the sequence of nucleotides in a DNA molecule, facilitate in-depth genetic examination, a factor that is vital for identifying genetic variations related to diseases and furthering precision medicine. For example, Illumina Inc., an American biotechnology organization, unveiled the Illumina Complete Long Read Technology in March 2023. This innovation supports both long-read and short-read sequencing in a single device, thereby significantly improving versatility in genomic science. By decreasing DNA input necessity and simplifying workflow, it eases the procedure for preparing libraries particularly for difficult samples. The technology offers excellent accuracy in variant calling, generating reliable data that is crucial for all-inclusive genomic examination.

What are the major segments of the epigenetics market and their role in driving growth?
The epigenetics market covered in this report is segmented -

1) By Product: Reagents, Enzymes, Instruments, Kits
2) By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures
3) By Application: Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications
4) By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Other End Users

Subsegments:
1) By Reagents: DNA Methylation Reagents, Histone Modification Reagents, RNA Modifications Reagents, Enzymes
2) By Enzymes: DNA Methyltransferases, Histone Acetyltransferases, Histone Deacetylases, Other Epigenetic Enzymes
3) By Instruments: Sequencers, PCR Machines, Microarray Platforms, Mass Spectrometers
4) By Kits: DNA Methylation Kits, Chromatin Immunoprecipitation (ChIP) Kits, RNA-Seq Kits, Bisulfite Conversion Kits

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7070

Which regions are key players in the growth of the epigenetics market?
North America was the largest region in the epigenetics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the epigenetics market during the forecast period. The regions covered in the epigenetics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the key firms paving the way for growth in the epigenetics market?
Major companies operating in the epigenetics market include Illumina Inc., Thermo Fisher Scientific, Merck Millipore, Active Motif, Abcam PLC, Qiagen NV, Diagenode SA, CellCentric Ltd., Chroma Medicine Inc., Constellation Pharmaceuticals Inc., Domainex Ltd., Eisai Co. Ltd., Epigen Biosciences Inc., EpigenDx Inc., Epigenomics AG, Epizyme Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., Locus Biosciences Inc., MDxHealth SA, Novartis AG, OncoDNA SA, Oryzon Genomics S.A., Pfizer Inc., Syndax Pharmaceuticals Inc., Valirx plc

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=7070&type=smp

What Is Covered In The Epigenetics Global Market Report?

•Market Size Forecast: Examine the epigenetics market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the epigenetics market for a structured understanding.
•Key Players Overview: Analyze major players in the epigenetics market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the epigenetics market.
•Segment Contributions: Evaluate how different segments drive overall growth in the epigenetics market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the epigenetics market.
•Industry Challenges: Identify potential risks and obstacles affecting the epigenetics market.
•Competitive Landscape: Review strategic developments in the epigenetics market, including expansions, agreements, and new product launches.

Americas: +1 315 623 0293

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.